Ubs Group Ag Genfit S.A. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Genfit S.A. stock. As of the latest transaction made, Ubs Group Ag holds 3,048 shares of GNFT stock, worth $11,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,048

Holding current value

$11,064

% of portfolio

0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.66 - $6.33 $11,155 - $19,293	3,048 New	3,048 $11,000
Q2 2024 Aug 13, 2024	BUY	$3.41 - $5.92 $1,179 - $2,048	346 New	346 $1,000
Q4 2023 Feb 09, 2024	BUY	$2.97 - $3.94 $3,376 - $4,479	1,137 New	1,137 $4,000
Q2 2023 Aug 11, 2023	BUY	$3.54 - $4.68 $11,929 - $15,771	3,370 Added 351.04%	4,330 $15,000
Q1 2023 May 12, 2023	SELL	$3.93 - $4.69 $14,851 - $17,723	-3,779 Reduced 79.74%	960 $3,000
Q4 2022 Feb 08, 2023	BUY	$3.53 - $4.39 $15,510 - $19,289	4,394 Added 1273.62%	4,739 $20,000
Q3 2022 Nov 10, 2022	SELL	$3.26 - $4.86 $6,017 - $8,971	-1,846 Reduced 84.25%	345 $1,000
Q2 2022 Aug 10, 2022	BUY	$3.09 - $4.25 $3,361 - $4,624	1,088 Added 98.64%	2,191 $7,000
Q1 2022 May 16, 2022	SELL	$3.14 - $5.04 $81 - $131	-26 Reduced 2.3%	1,103 $4,000
Q4 2021 Feb 14, 2022	SELL	$3.01 - $5.65 $7,594 - $14,254	-2,523 Reduced 69.09%	1,129 $6,000
Q3 2021 Nov 15, 2021	BUY	$3.58 - $4.14 $4,174 - $4,827	1,166 Added 46.9%	3,652 $14,000
Q2 2021 Aug 13, 2021	SELL	$3.8 - $4.63 $3,853 - $4,694	-1,014 Reduced 28.97%	2,486 $9,000
Q1 2021 May 12, 2021	BUY	$4.53 - $6.06 $15,855 - $21,210	3,500 New	3,500 $16,000
Q3 2020 Nov 12, 2020	SELL	$3.67 - $5.59 $4,671 - $7,116	-1,273 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$5.2 - $22.0 $6,619 - $28,006	1,273 New	1,273 $7,000
Q4 2019 Feb 14, 2020	SELL	$13.55 - $20.14 $18,333 - $27,249	-1,353 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.92 - $19.94 $20,186 - $26,978	1,353 New	1,353 $24,000

Others Institutions Holding GNFT

# of Institutions

Shares Held

205K

Call Options Held

Put Options Held

View Full List

About Genfit S.A.

Ticker GNFT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,815,500
Market Cap $181M
Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...

More about GNFT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account